A Double-masked, Sham Controlled, Dose-ranging Study to Evaluate the Safety and Effectiveness of Low Voltage Stereotactic Radiosurgery in Patients With Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD) (INTREPID)

NCT01016873 Phase 2 COMPLETED Results posted

The purpose of this study is to confirm the safety and establish the effectiveness of two doses from the IRay System for the treatment of wet AMD.

Details

Lead sponsor	Oraya Therapeutics, Inc.
Phase	Phase 2
Status	COMPLETED
Enrolment	230
Start date	2009-11
Completion	2014-04

Conditions

• AMD
• Wet AMD
• Age-Related Macular Degeneration
• Wet Age-Related Macular Degeneration
• Macular Degeneration
• Eye Diseases
• Retinal Diseases

Interventions

• IRay

Primary outcomes

• Number of Lucentis® Injections Up To And Including Week 52 — During the first 52 weeks.

Countries

Austria, Czechia, Germany, Italy, United Kingdom